Incannex Healthcare Inc. (IXHL)
IXHL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/0001628280-26-063506-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | IXHL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001873875 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$19.3M |
| Operating income | -$23.0M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $67.7M |
| Total assets | $73.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $68.3M cash; operating cash flow -$796K a quarter. | Report 2026-09-30 |
| Shares outstanding | 12,546,030 (2026-11-09); 346,225,507 a year earlier; 15,873,113 three years earlier. 1y figure adjusted for split (1-for-30 overall); 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2026-02-27 | Source 2026-02-27 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Audit Pty Ltd, Perth, Australia | PCAOB Form AP 2026-10-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $0 | -$1.9M | $521K | $68.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2026 2026-06-30 | Not filed | -$2.5M | $3.4M | $67.7M | No debt tags | $0 | 10-K 2026-09-25 |
| Q3 2026 2026-03-31 | Not filed | -$3.9M | -$2.5M | $74.5M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2026 2025-12-31 | Not filed | -$6.5M | -$4.6M | $68.9M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q1 2026 2025-09-30 | $0 | -$6.4M | -$9.2M | $73.3M | No debt tags | $12K | 10-Q 2026-11-12 |
| Q4 2025 2025-06-30 | $0 | -$31.6M | -$1.5M | $15.0M | No debt tags | $86K | 10-K 2026-09-25 |
| Q3 2025 2025-03-31 | $0 | -$4.0M | -$3.2M | $6.7M | $1.4M | Needs four quarters | 10-Q 2025-05-15 |
| Q2 2025 2024-12-31 | $12K | -$5.9M | -$5.6M | $2.1M | $3.8M | Needs four quarters | 10-Q 2025-02-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-03-12 |
| Latest annual report | 10-K | 2026-09-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-09 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-10-28 |
Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.1% |
| 1 month | -32.3% |
| 3 months | -37.7% |
| Year to date | -81.7% |
| 1 year | -81.6% |
| From 52-week high | -86.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BYSI | BeyondSpring Inc. | $0.5788 | -3.73% | $23.8M |
| FLNA | Filana Therapeutics Inc. | $0.4700 | +10.56% | $23.6M |
| GRDX | GridAI Technologies Corp. | $3.30 | -11.76% | $23.5M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier